Whole Genome Sequence-Based Analyses of Drug Resistance Characteristics, Genetic Diversity, and Transmission Dynamics of Drug-Resistant in Urumqi City

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2024 Mar 28

PMID 38544963

Authors

Jiandong Yang

Yaoqin Lu

Yanggui Chen

Yida Wang

Kai Wang

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to analyze the drug resistance spectrum, genetic diversity, and transmission dynamics to provide a basis for the prevention and control of drug-resistant (DR) tuberculosis (TB) epidemics.

Methods: This retrospective study is based on routine national drug resistance surveillance. The demographic, epidemiological, and clinical information on DR-TB patients from 2016 to 2021 was collected and used for phenotypic drug susceptibility testing and whole-genome sequencing.

Results: It was indicated that L2.2.1 was the dominant lineage in Urumqi. The drug resistance spectrum in Urumqi was narrow, which means more drug combinations can be used for clinical treatment. Furthermore, mutations identification of drug-resistance gene and are important for clinical drug use. However, mutations in cross-resistance genes have limited guidance for clinical selection of KM, CPM and AK. Moreover, there is an increased risk of cluster transmission of DR-TB, and the difference in clustering rate among L2, L3, and L4 was not statistically significant ( = 2.6410, = 0.2670).

Conclusion: In the Urumqi, DR-TB has a complex prevalence state, a narrow drug resistance spectrum, and a high clustering rate and burden of drug resistance. To reduce the burden of DR-TB, related research should be strengthened, and the development of prevention, control, and treatment strategies should be accelerated.

Citing Articles

Genotypic Antimicrobial Resistance Profiles of Diarrheagenic and Nontyphoidal Strains Isolated from Children with Diarrhea and Their Exposure Environments in Ethiopia.

Belina D, Gobena T, Kebede A, Chimdessa M, Hald T Infect Drug Resist. 2024; 17:4955-4972.

PMID: 39539744 PMC: 11559196. DOI: 10.2147/IDR.S480395.

References

Dreyer V, Mandal A, Dev P, Merker M, Barilar I, Utpatel C . High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region. Genome Med. 2022; 14(1):95. PMC: 9394022. DOI: 10.1186/s13073-022-01076-0. View

Oladimeji O, Atiba B, Anyiam F, Odugbemi B, Afolaranmi T, Zoakah A . Gender and Drug-Resistant Tuberculosis in Nigeria. Trop Med Infect Dis. 2023; 8(2). PMC: 9964483. DOI: 10.3390/tropicalmed8020104. View

Nieuwenhuijse D, van der Linden A, Kohl R, Sikkema R, Koopmans M, Oude Munnink B . Towards reliable whole genome sequencing for outbreak preparedness and response. BMC Genomics. 2022; 23(1):569. PMC: 9361258. DOI: 10.1186/s12864-022-08749-5. View

Eyre D . Infection prevention and control insights from a decade of pathogen whole-genome sequencing. J Hosp Infect. 2022; 122:180-186. PMC: 8837474. DOI: 10.1016/j.jhin.2022.01.024. View

Zhao Y, Xu S, Wang L, Chin D, Wang S, Jiang G . National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012; 366(23):2161-70. DOI: 10.1056/NEJMoa1108789. View

Zheng Y, Zhang X, Wang X, Wang K, Cui Y . Predictive study of tuberculosis incidence by time series method and Elman neural network in Kashgar, China. BMJ Open. 2021; 11(1):e041040. PMC: 7825257. DOI: 10.1136/bmjopen-2020-041040. View

Nasiri M, Zamani S, Pormohammad A, Feizabadi M, Aslani H, Amin M . The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran. Eur J Clin Microbiol Infect Dis. 2017; 37(1):9-14. DOI: 10.1007/s10096-017-3079-4. View

Somoskovi A, Helbling P, Deggim V, Homke R, Ritter C, Bottger E . Transmission of multidrug-resistant tuberculosis in a low-incidence setting, Switzerland, 2006 to 2012. Euro Surveill. 2014; 19(11). DOI: 10.2807/1560-7917.es2014.19.11.20736. View

He W, Tan Y, Liu C, Wang Y, He P, Song Z . Drug-Resistant Characteristics, Genetic Diversity, and Transmission Dynamics of Rifampicin-Resistant Mycobacterium tuberculosis in Hunan, China, Revealed by Whole-Genome Sequencing. Microbiol Spectr. 2022; 10(1):e0154321. PMC: 8849054. DOI: 10.1128/spectrum.01543-21. View

10.

Okethwangu D, Birungi D, Biribawa C, Kwesiga B, Turyahabwe S, Ario A . Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013-2017. BMC Infect Dis. 2019; 19(1):387. PMC: 6503550. DOI: 10.1186/s12879-019-4014-3. View

11.

Kant S, Tyagi R . The impact of COVID-19 on tuberculosis: challenges and opportunities. Ther Adv Infect Dis. 2021; 8:20499361211016973. PMC: 8193657. DOI: 10.1177/20499361211016973. View

12.

Zhang M, Zhou L, Zhang Y, Chen B, Peng Y, Wang F . Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China. Eur J Med Res. 2021; 26(1):31. PMC: 8019161. DOI: 10.1186/s40001-021-00502-0. View

13.

Qi Z, Gao X, Wang Y, Liu C . Epidemic characteristics and drug resistance of tuberculosis in North China. Heliyon. 2020; 6(9):e04945. PMC: 7502568. DOI: 10.1016/j.heliyon.2020.e04945. View

14.

Suzuki T, Ley R . The role of the microbiota in human genetic adaptation. Science. 2020; 370(6521). DOI: 10.1126/science.aaz6827. View

15.

Coll F, McNerney R, Guerra-Assuncao J, Glynn J, Perdigao J, Viveiros M . A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014; 5:4812. PMC: 4166679. DOI: 10.1038/ncomms5812. View

16.

Maus C, Plikaytis B, Shinnick T . Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005; 49(8):3192-7. PMC: 1196259. DOI: 10.1128/AAC.49.8.3192-3197.2005. View

17.

Tiberi S, Utjesanovic N, Galvin J, Centis R, DAmbrosio L, Boom M . Drug resistant TB - latest developments in epidemiology, diagnostics and management. Int J Infect Dis. 2022; 124 Suppl 1:S20-S25. DOI: 10.1016/j.ijid.2022.03.026. View

18.

Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott A . The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med. 2022; 10(6):603-622. PMC: 8942481. DOI: 10.1016/S2213-2600(22)00092-3. View

19.

Leddy A, Jaganath D, Triasih R, Wobudeya E, Bellotti de Oliveira M, Sheremeta Y . Social Determinants of Adherence to Treatment for Tuberculosis Infection and Disease Among Children, Adolescents, and Young Adults: A Narrative Review. J Pediatric Infect Dis Soc. 2022; 11(Supplement_3):S79-S84. PMC: 9620428. DOI: 10.1093/jpids/piac058. View

20.

Tiberi S, Vjecha M, Zumla A, Galvin J, Migliori G, Zumla A . Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. Int J Infect Dis. 2021; 113 Suppl 1:S96-S99. PMC: 7944856. DOI: 10.1016/j.ijid.2021.02.067. View